scholarly journals Antibody and Viral Nucleic Acid Testing of Serum and Cerebrospinal Fluid for Diagnosis of Eastern Equine Encephalitis

2015 ◽  
Vol 53 (8) ◽  
pp. 2768-2772 ◽  
Author(s):  
James A. Sherwood ◽  
David C. Brittain ◽  
John J. Howard ◽  
JoAnne Oliver

Eastern equine encephalitis diagnostic serum antibody can appear 6 days after the onset of symptoms, and its numbers can increase 4-fold in 4 days, arguing for early and frequent serum testing. In populations where cerebrospinal fluid viral nucleic acid testing sensitivity and specificity remain undetermined, cerebrospinal antibody testing should also be performed.

2020 ◽  
Vol 215 (4) ◽  
pp. 834-838 ◽  
Author(s):  
Joseph V. Waller ◽  
Parveer Kaur ◽  
Amy Tucker ◽  
Keldon K. Lin ◽  
Michael J. Diaz ◽  
...  

Lab on a Chip ◽  
2018 ◽  
Vol 18 (13) ◽  
pp. 1928-1935 ◽  
Author(s):  
Wenhan Liu ◽  
Jagotamoy Das ◽  
Adam H. Mepham ◽  
Carine R. Nemr ◽  
Edward H. Sargent ◽  
...  

Integrated devices for automated nucleic acid testing (NAT) are critical for infectious disease diagnosis to be performed outside of centralized laboratories.


Transfusion ◽  
2008 ◽  
Vol 48 (5) ◽  
pp. 822-826 ◽  
Author(s):  
C. Micha Nübling ◽  
Uwe Unkelbach ◽  
Michael Chudy ◽  
Rainer Seitz

2020 ◽  
Author(s):  
Dan Liu ◽  
Chenhui Ju ◽  
Chao Han ◽  
Rui Shi ◽  
Xuehui Chen ◽  
...  

AbstractThe recently emerged coronavirus disease COVID-19 has now evolved into a global pandemic. Early detection is crucial for its effective control. Nucleic acid testing for viral pathogen and serological testing for host antibodies are playing important roles in current COVID-19 diagnosis. However, while nucleic acid testing is complicated, facility-restricted and time-consuming, antibody testing may result in high rates of false-negative diagnoses, especially during the early stages of viral infection. Thus, a more rapid and reliable test for both early COVID-19 diagnosis and whole-population screening is urgently needed. Here, we developed a novel nanozyme-based chemiluminescence paper assay for rapid and high-sensitive testing of SARS-CoV-2 spike antigen. Our paper test uses a newly established peroxidase-mimic Co-Fe@hemin nanozyme instead of natural HRP that catalytically amplifies the chemiluminescent signal, allowing for target concentrations to be as low as 0.1 ng/ml. Furthermore, our nanozyme-based chemiluminescence test exhibits a linear range that is 32-fold wider compared to ELISA tests. Importantly, testing is completed in less than 16 min, compared to 1-2 h required for ELISA or nucleic acid tests. Critically, signal detection is feasible using a smartphone camera. Ingredients for our test are simple and readily available, rendering overall cost considerably lower than those used in current diagnoses. In conclusion, our novel test provides a high-sensitive, point-of-care testing (POCT) approach for SARS-CoV-2 antigen detection, which should greatly increase current early screening capacities for suspected infections, and considerably lower demand for national healthcare resources.


2009 ◽  
Vol 9 (3) ◽  
pp. 620-628 ◽  
Author(s):  
L. M. Kucirka ◽  
C. Alexander ◽  
R. Namuyinga ◽  
C. Hanrahan ◽  
R. A. Montgomery ◽  
...  

2020 ◽  
Vol 63 (10) ◽  
pp. 1498-1506 ◽  
Author(s):  
Fei Tian ◽  
Chao Liu ◽  
Jinqi Deng ◽  
Ziwei Han ◽  
Lu Zhang ◽  
...  

2014 ◽  
Vol 155 (26) ◽  
pp. 1019-1023
Author(s):  
Judit Gervain

The successful therapy of hepatitis C viral infection requires that the illness is diagnosed before the development of structural changes of the liver. Testing is stepwise consisting of screening, diagnosis, and anti-viral therapy follow-up. For these steps there are different biochemical, serological, histological and molecular biological methods available. For screening, alanine aminotransferase and anti-HCV tests are used. The diagnosis of infection is confirmed using real-time polymerase chain reaction of the viral nucleic acid. Before initiation of the therapy liver biopsy is recommended to determine the level of structural changes in the liver. Alternatively, transient elastography or blood biomarkers may be also used for this purpose. Differential diagnosis should exclude the co-existence of other viral infections and chronic hepatitis due to other origin, with special attention to the presence of autoantibodies. The outcome of the antiviral therapy and the length of treatment are mainly determined by the viral genotype. In Hungary, most patients are infected with genotype 1, subtype b. The polymorphism type that occurs in the single nucleotide located next to the interleukin 28B region in chromosome 19 and the viral polymorphism type Q80K for infection with HCV 1a serve as predictive therapeutic markers. The follow-up of therapy is based on the quantitative determination of viral nucleic acid according to national and international protocols and should use the same method and laboratory throughout the treatment of an individual patient. Orv. Hetil., 2014, 155(26), 1019–1023.


2011 ◽  
Vol 8 (3) ◽  
pp. 235-244 ◽  
Author(s):  
Mahmoud Elsabahy ◽  
Adil Nazarali ◽  
Marianna Foldvari

Sign in / Sign up

Export Citation Format

Share Document